Evidence Explorer · MS-N244 · Exercise and rehabilitation · fatigue, sleep and physical function · Appraised November 5, 2026
A single-center randomized phase II study reported less fatigue and better sleep and physical-function measures with personalized breathing and aerobic exercise during neoadjuvant immunochemotherapy. Accessible reporting does not establish tumor-response or survival benefit.
Evidence at a glance
- Benefit signal: Favorable patient-reported fatigue, sleep and function signals after two to three treatment cycles.
- Certainty: Low. The trial was open label and single center, and the accessible abstract did not report all absolute effects, confidence intervals or adverse events.
- Risk context: Head-and-neck symptoms, airway issues, swallowing problems, anemia and treatment toxicity may require frequent adjustment.
- Cancer-control relevance: Supportive symptoms and function only; biomarker or symptom changes cannot be interpreted as tumor control.
What was studied
The phase II study randomized 114 people receiving neoadjuvant immunochemotherapy for head-and-neck squamous-cell carcinoma to personalized breathing plus aerobic exercise or routine care.
Outcomes included Brief Fatigue Inventory, Pittsburgh Sleep Quality Index and quality-of-life domains across treatment cycles.
What the study found
After two and three cycles, the intervention group had lower fatigue scores, while sleep outcomes improved relative to worsening in the control group. Physical function, fatigue and insomnia domains also favored the intervention.
The accessible abstract did not provide enough absolute between-group estimates and confidence intervals to judge clinical importance precisely.
What this does not establish
An unblinded supportive-care intervention can influence self-reported outcomes through attention and expectation. The trial does not show improved pathologic response, recurrence or survival, and the generalizability of a single-center personalized program is uncertain.
Safety and practical context
Airway compromise, infection, severe mucositis, dizziness, dehydration or cardiopulmonary symptoms require clinical review before exercise continues.
Breathing exercises should not delay assessment of stridor, rapidly worsening breathlessness or aspiration risk.
Questions for the care team
- Are airway, swallowing or anemia concerns likely to change the plan?
- Which fatigue or sleep measure will we use to decide whether it is helping?
- Can a rehabilitation professional adapt sessions around infusion and symptom peaks?
Sources and identifiers
Funding and conflicts: Not reported in the accessible abstract and not independently verified.
Source access and dates: Abstract-level appraisal; complete numeric outcome, adverse-event and conflict disclosures were not verified. Sources checked November 5, 2026. Last literature search November 5, 2026.
Educational evidence summary, not individualized medical advice. Exercise around cancer treatment should be adapted to symptoms, blood counts, bone health, cardiopulmonary status, surgical restrictions and the treating team’s guidance.
